Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, Hitoshi Arioka, Hirotoshi Iihara, Mitsuhiro Sugawara, Hajime Morita, Ayako Mochizuki, Shuichi Nawata, Keisuke Mishima, Ayako Tsuboya, Tempei Miyaji, Kazunori Honda, Ayako Yokomizo, Naoya Hashimoto, Takeshi Yanagihara, Junki Endo, Takashi Kawaguchi, Naoki Furuya, Yumiko Sone, Yusuke Inada, Yasushi Ohno, Chikatoshi Katada, Naoya Hida, Kana Akiyama, Daisuke Ichikura, Akiko Konomatsu, Takashi Ogura, Takuhiro Yamaguchi, Takako Eguchi Nakajima
BACKGROUND: This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with sparing on days 2-4 in cisplatin-based chemotherapy. METHODS: Patients with malignant solid tumors who were treated with cisplatin (≥50 mg/m²) were randomly assigned (1:1) to receive either DEX on days 1-4 (Arm D4) or DEX on day 1 (Arm D1) plus palonosetron, NK-1 RA, and olanzapine (5 mg). The primary endpoint was complete response (CR) during the delayed (24-120 h) phase...
November 16, 2023: British Journal of Cancer